Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JOHNSON & JOHNSONJNJ · Entity 2722 | EVP, WW Chair, MedTech | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JOHNSON & JOHNSON
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,447 |
Ending reported balance
After 2026-09-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-02 · Exercise / conversion · Acquired 11,070 · Balance 36,517 Row 2 · 2026-09-02 · Sale · Disposed 11,070 · Balance 25,447 Row 3 · 2026-09-02 · Exercise / conversion · Acquired 22,527 · Balance 47,974 Row 4 · 2026-09-02 · Sale · Disposed 22,527 · Balance 25,447 |
| Employee Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.94 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2026-09-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-02 · Exercise / conversion · Disposed 11,070 · Balance 0 F3: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. |
| Employee Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $151.41 · Expires 2030-02-10 | Direct | 0 |
Reported balance
After 2026-09-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-02 · Exercise / conversion · Disposed 22,527 · Balance 0 F3: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. |
| Common StockSEC Table I · non-derivative | IndirectBy 401k | 758 |
Reported balance
Holding disclosure · report date 2026-09-02 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 758 F1: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (8/31/2026). |
| Common StockSEC Table I · non-derivative | IndirectBy ESOP | 46 |
Reported balance
Holding disclosure · report date 2026-09-02 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 46 F2: Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (8/31/2026). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (8/31/2026).
F2: Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (8/31/2026).
F3: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2024 Filed Feb 15, 2024 21:53 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 499 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002179 · doc4.xml · nonDerivative · entry 1 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Share Units awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 23:36 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionPerformance Share Units · Derivative | 4,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002101 · doc4.xml · derivative · entry 6 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,911 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Performance Share Units awarded on February 8, 2021; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board on February 12, 2024. F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. Performance Share Units awarded on February 8, 2021; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board on February 12, 2024. F1 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. Performance Share Units awarded on February 8, 2021; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board on February 12, 2024. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 23:36 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 2,887 | $157.40 | $454,413.80 |
DisclosureSEC source: 0001225208-24-002101 · doc4.xml · nonDerivative · entry 3 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,791 F3 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units and certification of performance results by the Board. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 23:36 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 825 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002101 · doc4.xml · nonDerivative · entry 2 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Shares earned due to performance factor of 116.8% upon certification of performance results by the Board. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 23:36 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 4,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002101 · doc4.xml · nonDerivative · entry 1 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Awarded under Issuer's Long-Term Incentive Plan. Performance Share Units awarded on February 8, 2021; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board on February 12, 2024. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 00:24 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 1,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001894 · doc4.xml · derivative · entry 5 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,964 shares Expires 2024-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Share Units awarded under Long-Term Incentive Plan on February 8, 2021 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. F1 · derivative.exercise_date: Restricted Share Units awarded under Long-Term Incentive Plan on February 8, 2021 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. F1 · derivative.expiration_date: Restricted Share Units awarded under Long-Term Incentive Plan on February 8, 2021 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 00:24 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 1,001 | $156.33 | $156,486.33 |
DisclosureSEC source: 0001225208-24-001894 · doc4.xml · nonDerivative · entry 2 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,942 F2 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 00:24 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 1,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001894 · doc4.xml · nonDerivative · entry 1 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Share Units awarded under Long-Term Incentive Plan on February 8, 2021 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.